Sanofi Stock in 2026: Share Price, Dividend and Dupixent

Sanofi stock (ticker SAN in Paris) is one of the most dynamic stories in the French pharmaceutical sector in 2026: the drugmaker is posting double-digit sales growth (+17.8% in the second quarter), driven by Dupixent — its star immunology drug, which has just topped €5 billion in sales in a single quarter for the first time — and has raised its 2026 targets (sales ~+10% at constant exchange rates) while setting a 2030 ambition of €25 billion in Dupixent sales. The dividend, meanwhile, has risen for 31 consecutive years (€4.12 paid in 2026). Yet the stock remains around €72, well below analysts’ average targets (~€93), weighed down by a change in leadership, a pipeline being streamlined and a dispute with Regeneron. Dupixent, the dividend, the new management: there is a lot to cover, and this page walks through it all.

Sanofi Share Price Live

The drugmaker is listed on Euronext Paris under the ticker SAN, with a line on the NYSE (SNY). The stock is part of the CAC 40 and the Euro Stoxx 50, and is PEA-eligible. In autumn 2026, the stock trades at around €72, with a 52-week range of roughly €65 to €90 — the stock has had a mixed year, lifted by Dupixent’s strong results but held back by uncertainty over the pipeline and governance. Market capitalization is around €90 billion, making it one of the largest pharmaceutical companies in Europe by market value. Liquidity is excellent (several million shares traded per day). For real-time quotes, the reference remains the stock’s Boursorama page.

To compare with other healthcare stocks, also see our analysis of Rockwell Medical stock and of Santé stock.

Sanofi Stock Profile

CompanySanofi S.A.
Ticker / SymbolSAN (Euronext Paris); SNY (NYSE)
ISINFR0000120578 (France)
Listing venuesEuronext Paris, New York Stock Exchange
SectorPharmaceuticals: immunology, rare diseases, vaccines, oncology, neurology
PEA eligibilityYes — the Paris line is PEA-eligible
Chief executiveBelén Garijo (CEO, expanded leadership team since September 2026)
HeadquartersParis (France)
IndexCAC 40, Euro Stoxx 50

The group and its businesses

Sanofi is one of the world’s largest pharmaceutical companies, active in immunology (Dupixent, Kevzara), rare diseases (ALTUVIIIO, hematology), vaccines (flu, COVID, pneumococcal, Heplisav-B), oncology (Sarclisa, Rezurock) and neurology (venglustat for Gaucher disease). The heart of the investment case is Dupixent (dupilumab), developed jointly with Regeneron, which treats severe asthma, atopic dermatitis, chronic rhinosinusitis with nasal polyps, eosinophilic esophagitis and other indications — with growth of +34.4% in the first half of 2026 (€9.3 billion) and a 2030 ambition of ~€25 billion in annual sales. The other growth drivers are recent launches (Sarclisa in oncology, Rezurock, Myqorzo in cardiology, ALTUVIIIO in hematology), expected to generate about €5.2–5.3 billion in sales in 2026. The acquisition of Dynavax (vaccines, ~€1.6 billion), completed in 2026, strengthens the immunology portfolio, at the cost of net debt rising to €15.5 billion (vs. €11 billion at the start of the year — the effect of Dynavax, a €4.9 billion dividend and a €1 billion share buyback).

Who owns Sanofi?

The share capital is largely free-floating, spread among major international institutions, healthcare funds and retail investors — with no controlling shareholder (the French state has not been a shareholder for years). This free float explains the stock’s sensitivity to pipeline and governance news: every regulatory decision (FDA, EMA) or management change feeds straight into the share price, with no buffer. That is typical of big pharma: strong visibility on the present (Dupixent), but structural uncertainty about the future (pipeline, patents, competition).

Sanofi History and Strategy

In 2026, the drugmaker is going through a major leadership transition: Paul Hudson, CEO since 2019, has stepped down; Belén Garijo has taken over as CEO (after an interim period under Olivier Charmeil) with a streamlined leadership team since September 1, 2026. This reorganization comes amid exceptional commercial performance (Dupixent up 37.6% in Q2, 2026 guidance raised to ~+10% sales growth) but a pipeline being streamlined: amlitelimab discontinued (atopic dermatitis), venglustat kept in Phase 3 for Gaucher disease type 3 (FDA decision expected on November 25, 2026), the European filing for bullous pemphigoid withdrawn, and an ongoing dispute with Regeneron over Dupixent rebates.

The medium-term strategy rests on three pillars: maximizing Dupixent (new indications, geographies, optimized treatment regimens), accelerating launches (Sarclisa, Rezurock, Myqorzo, ALTUVIIIO — a target of ~€10 billion in combined sales by 2030) and strengthening the pipeline through external growth (Dynavax, bolt-on opportunities identified by the new management). The dividend remains a pillar of shareholder relations — 31 consecutive years of increases make Sanofi one of Europe’s most solid dividend aristocrats.

Sanofi Financial Data

Main group trends (€ billions; published data and forecasts — check for updates):

Market data and history, updated automatically

SanofiSAN.PA · Paris
83,79 €-4,35 %
Clôture précédente87,60 €
Plus haut du jour85,75 €
Plus bas du jour81,93 €
Plus haut 52 semaines89,00 €
Plus bas 52 semaines69,75 €
Volume3 205 593
Capitalisation100,6 Md
PER24,2
Rendement du dividende4,76 %
Dividende par action4,12 €
Objectif moyen des analystes96,36 €
Mis à jour le 2026-11-19 18:45:52 · Source : Yahoo · Données indicatives, ne constituent pas un conseil en investissement.

Résultats annuels — Sanofi
Exercice clos leChiffre d’affairesRésultat net
2025-12-3143,63 Md €7,81 Md €
2024-12-3141,08 Md €5,74 Md €
2023-12-3143,07 Md €5,40 Md €
2022-12-3143,00 Md €6,72 Md €
Source : Yahoo Finance · Collecté le 2026-11-19 17:45:53 UTC · Données historiques indicatives, non temps réel.

Historique des dividendes — Sanofi
Date de détachementMontant par action
2026-05-054,120 €
2025-05-123,920 €
2024-05-133,760 €
2023-05-303,560 €
2022-05-063,330 €
Source : Yahoo Finance · Collecté le 2026-11-19 17:45:53 UTC · Données historiques indicatives, non temps réel.

Source: Yahoo Finance, data collected by the server (collection date shown under each block). Indicative data, not investment advice.

ISINFR0000120578
Exchange and tickerParis — SAN.PA
SectorHealthcare
P/E (TTM)21.8 (as of October 19, 2026)
Indicative dividend yield5.73% (as of October 19, 2026)
Indicator2025Q1 2026 (actual)Q2 2026 (actual)2026 (estimate)
Revenue~€42.4B€10.5B (+13.6% CER)€11.6B (+17.8% CER)~+10% CER (raised guidance)
Dupixent (sales)~€14.1B€4.17B (+30.8%)€5.15B (+37.6%)~€16B (estimated)
Business EPS (reported)~€6.50€1.88 (+5.0% reported / +14% CER)€2.09 (+33.3% reported)Growth slightly > sales
Dividend per share€4.12 (31st consecutive increase)——~€4.26 (consensus estimate)
Net debt~€11.0B—€15.5B (Dynavax + dividend + buyback effect)Stabilization expected

The first half of 2026 was excellent: cumulative revenue up by double digits (+13.6% in Q1, +17.8% in Q2 at constant exchange rates), Dupixent topping €5 billion in a single quarter for the first time (+37.6%), and solid growth in business EPS (Q1: €1.88; Q2: €2.09). 2026 guidance was raised to ~+10% sales growth at constant exchange rates, with business EPS growing slightly faster — in line with management’s ambition of profitable growth. The balance sheet absorbed the capital transactions (Dynavax ~€1.6B, a €4.9B dividend, a €1B share buyback completed in April), bringing net debt to €15.5 billion at the end of June — a manageable level for a drugmaker generating more than €10 billion in operating cash flow per year, but one to watch if external growth continues. The consensus expects a dividend of €4.26 for 2026 (+3.4%), continuing the historical streak.

Recent dividend history

Ex-dividend dateAmount per share
May 5, 2026€4.12
May 12, 2025€3.92
May 13, 2024€3.76
May 30, 2023€3.56

Yahoo Finance — data verified on October 19, 2026: share price and fundamentals, ex-dividend history. Market data is indicative and does not constitute investment advice.

Sanofi Stock Technical Analysis

The chart shows a broad consolidation after a year of mixed performance: the stock has swung between €65 and €90, with no clear directional trend — reflecting the debate between exceptional commercial performance (Dupixent) and structural uncertainties (pipeline, governance, the Regeneron dispute). The 50-day and 200-day moving averages are converging around €70–75, a sign of accumulation rather than distribution. Levels to watch: support at €65–68 (the year’s low) and resistance at €80–85 (the area of the spring highs), a break above which would revive upward momentum toward €93 (the consensus average target). The next catalyst is the third-quarter results release on October 30, 2026, followed by the FDA decision on venglustat on November 25 — two events that could unlock the stock. Technically, after several months of consolidation, the stock offers a patient accumulation profile — ideally, buy on support, not on resistance.

Sanofi Stock Consensus and Price Targets

The analyst consensus is positive: at Zonebourse (25 analysts tracked in October 2026), the average recommendation is “ACCUMULATE” with an average price target of €93.35 — a theoretical upside of +29% from the current price of ~€72. Revisions have been positive since the 2026 guidance upgrade and the Dupixent 2030 ambition; RBC Capital Markets maintains a neutral rating (October 2026), considering the stock fairly valued in the short term. The letter of intent signed with the pan-Canadian Pharmaceutical Alliance (October 15, 2026) for four additional Dupixent indications illustrates the drug’s continued geographic expansion.

The metrics to track are the Dupixent trajectory (the ~€16 billion guidance for 2026 and the €25 billion ambition for 2030 underpin the thesis), launch performance (target of €5.2–5.3 billion in 2026, ~€10 billion in 2030) and debt management (the post-Dynavax deleveraging path). The calendar: Q3 on October 30, the FDA venglustat decision on November 25, then the spring 2027 AGM for the dividend.

Sanofi Stock Dividend

Sanofi is one of Europe’s most solid dividend aristocrats: 31 consecutive years of dividend increases, a rare track record in the pharmaceutical sector. The dividend for 2025 was €4.12 per share, approved by shareholders at the annual general meeting on April 29, 2026 and paid in the spring. The gross yield at the current share price is close to 5.7–5.8% — one of the highest in the CAC 40 for a quality large cap.

The consensus expects a dividend of €4.26 for 2026 (+3.4%) and €4.44 for 2027 — continuing the policy of steady growth. The payout ratio is around 60–65% of business earnings, consistent with the drugmaker’s maturity and its R&D investment needs. On top of the dividend, Sanofi carried out a €1 billion share buyback in 2026 (completed in April), with the shares to be canceled — a strong signal of confidence in the valuation. For an investor seeking yield backed by long-term dividend growth, Sanofi offers a unique profile: a dividend aristocrat yielding 5.7%, with Dupixent’s growth supporting its payout capacity.

Tableau originalDiversifiez votre patrimoineInvestissez dans l’artDes tableaux originaux, pièces uniques signées par l’artiste. Un actif tangible, loin des écrans et des cotations.Voir les tableaux →

Should You Buy Sanofi Stock in 2026?

The case for buying

  • Exceptional Dupixent growth: +34.4% in H1 2026, a €25B ambition for 2030 — a structural growth driver that goes beyond the usual pharmaceutical cycle.
  • Raised 2026 guidance: sales ~+10% CER, EPS growing slightly faster — among the best trajectories in the European sector.
  • A 5.7% dividend with 31 years of increases: a rare dividend aristocrat, backed by strong cash generation.
  • An attractive valuation: consensus average target +29%; P/E in line with the sector average despite stronger growth.
  • A motivated new management team: Belén Garijo, a streamlined team since September 2026, financial discipline and a focus on growth drivers.

The risks — read them twice

  • Concentration on Dupixent: more than 40% of sales depend on a single drug — any slowdown (competition, biosimilars from 2030 onward) would hurt the thesis.
  • A pipeline being streamlined: amlitelimab dropped, venglustat awaiting an FDA decision, the Regeneron dispute — renewing the portfolio is not a given.
  • Rising debt: €15.5B at the end of June (vs. €11B at the start of 2026) — the balance sheet needs watching, especially if external growth continues.
  • Growing competition: new entrants in immunology (AstraZeneca, AbbVie), pricing pressure and the medium-term risk of biosimilars.
  • The stock has already performed: P/E in line with the sector average, but future growth is partly priced in — a Dupixent disappointment would trigger a correction.

How to Buy Sanofi Stock from France

Step 1 — Open a PEA-compatible brokerage account

The stock is PEA-eligible, which gives you lighter taxation on dividends after five years of holding (17.2% social charges instead of 30%, and exemption from income tax after the fifth year). To compare brokerage offers (fees, app quality, data access), see our platform comparison before opening your account.

Step 2 — Place a buy order

Look up the ticker SAN on Euronext Paris in your brokerage app. Given the stock’s liquidity, a market order is generally fine; a limit order around €68–72 can help improve your entry price if you believe in the Dupixent 2030 trajectory. Set the number of shares (the stock is very liquid) and confirm the order during the trading session.

Step 3 — Track the value milestones

Three events shape the investment case: the Q3 release on October 30, 2026, the FDA decision on venglustat on November 25, and full-year results in early 2027 (confirmation of guidance and the dividend trajectory). At each step, compare Dupixent growth, launch performance and the debt trajectory with the 2030 targets — the only reliable progress indicator for this kind of growth pharma story.

Sanofi Stock FAQ

Should you buy Sanofi stock in 2026?

The investment case combines exceptional growth (Dupixent +34% in H1, a €25B ambition for 2030), a 5.7% dividend with 31 years of increases and an attractive valuation (average target +29%) — all with a new management team in place since September. The risks are concentration on Dupixent, a pipeline being streamlined and higher debt after Dynavax. Buying makes sense for a patient investor who believes in the Dupixent trajectory and accepts pharmaceutical volatility; it is not recommended for those looking for an investment free of cycle or competition risk.

What is Dupixent and why does it matter so much for Sanofi?

Dupixent (dupilumab) is an immunology drug developed jointly with Regeneron that treats severe asthma, atopic dermatitis, chronic rhinosinusitis with nasal polyps, eosinophilic esophagitis and other indications. With €9.3 billion in sales in the first half of 2026 (+34.4%) and an ambition of €25 billion in 2030, Dupixent accounts for more than 40% of Sanofi’s sales and is the drugmaker’s main growth engine — which is why it is important to track new indications, future competition and the dispute with Regeneron over rebates.

What is the Sanofi dividend in 2026?

The dividend for 2025 was €4.12 per share, marking the 31st consecutive increase — a rare track record in Europe. It was approved by shareholders at the AGM on April 29, 2026 and paid in the spring. The consensus expects €4.26 for 2026 (+3.4%), a gross yield of about 5.7% at the current share price. Sanofi supplements the dividend with share buybacks (€1B completed in 2026).

Why is Sanofi changing its CEO?

Paul Hudson (CEO 2019–2026) has stepped down; Belén Garijo has taken over as CEO, with a streamlined leadership team since September 1, 2026. The change comes amid exceptional commercial performance (Dupixent) but a pipeline that needs renewing and financial discipline that needs reaffirming — the new management immediately raised 2026 guidance and has made the Dupixent 2030 ambition its strategic compass.

Is Sanofi exposed to the dispute with Regeneron?

Yes — there is an ongoing dispute between Sanofi and Regeneron over Dupixent rebates (the discounts granted to US payers). The two companies are partners on Dupixent (Regeneron develops the molecule, Sanofi markets it outside the United States), and profit sharing is at the heart of the disagreement. The dispute is at an early stage; its financial impact remains uncertain, but it is a legal risk to monitor — without calling into question the drug’s commercialization, which continues as normal.

What is the analysts’ price target for Sanofi?

The consensus (25 analysts, October 2026) is “ACCUMULATE” with an average target of €93.35 — a theoretical upside of +29% from the current price of ~€72. Revisions have been positive since the 2026 guidance upgrade and the Dupixent 2030 ambition; RBC remains neutral in the short term. The key metrics to track to validate the trajectory are Dupixent growth and launch performance (Sarclisa, Rezurock, Myqorzo).

Should you buy Sanofi stock?

The honest answer depends on your profile, and this page gives you the elements to work it out: on one side, a pipeline of drugs in development, potential licensing deals and a solid dividend track record; on the other, the risks specific to the sector — possible clinical failures, patent expiries and pricing pressure. Income investors see it as a defensive stock; growth investors watch the pipeline. The decision — buy, wait or pass — should follow your time horizon and the share this type of stock should hold in your portfolio: this page provides the figures, the method is yours.

What is this stock’s exact listing?

The stock trades on Euronext Paris under the code EPA: SAN — the EPA prefix designates the Paris exchange in financial terminals. Ticker: SAN, ISIN FR0000120578, a member of the CAC 40 — the “Share price” section of this page brings together the full details and live quote tracking.

Conclusion: A Quality Dividend Backed by a Growing Blockbuster

In 2026, Sanofi offers a rare profile: a pharmaceutical blockbuster with exceptional growth (Dupixent, a €25B ambition for 2030), a 5.7% dividend with 31 consecutive years of increases, and an attractive valuation (average target +29%). The risks are concentration on Dupixent, a pipeline being streamlined and higher debt after Dynavax — but the new management has set a clear course from the outset. For an investor looking for quality growth with solid income, a position is justified in a reasonable size, with Q3 on October 30 and the FDA decision on November 25 as the next milestones. To compare other growth-and-income profiles in the CAC 40, our pages on L’Oréal (global beauty) and Airbus (growing aerospace) are two natural complements.

Suivez-nous sur Telegram